I was introduced to Bayartis at Web Summit 2024, and their pitch immediately resonated with what we at YOUR R&D build in HealthTech: safer, smarter medication journeys for multi-med patients. In a world where adherence, interactions, and shelf-life all collide in the home, Bayartis is tackling polypharmacy with an elegant combo of intelligent storage and AI-assisted guidance.

💊 The Problem: Polypharmacy Is Rising—and Risky

Polypharmacy (taking multiple medications at once) is increasingly common among older adults and people with chronic conditions. It amplifies risks such as harmful drug–drug interactions, missed or duplicated doses, and improper storage/expiry. These issues cost health systems billions while quietly eroding patients’ quality of life. Bayartis centers their entire product narrative on this pain.

📉 What’s broken today

• Fragmented home storage (kitchen drawers, bathroom cabinets).
  
• Manual tracking of refills, expiries, and dose schedules.
  
• Limited visibility for caregivers and clinicians into real-world adherence.
  
• Confusing side-effect signals and no easy “what to do now” guidance.
  

🧠 The Bayartis Solution: Smart Cabinet + AI-Powered App

Bayartis proposes an integrated in-home system: a smart medicine cabinet that recognizes and monitors drugs (including OTC), keeps them under appropriate conditions, and synchronizes with a mobile app that handles reminders, stock/expiry alerts, and side-effect logging. It’s a tidy, consumer-friendly approach to bring order to the most chaotic part of care: the home.

Key capabilities they highlight:

• Centralized storage with proper conditions and visibility of what’s in stock.
  
• Usage + expiry tracking with proactive notifications.
  
• App-first guidance for adherence, side-effects, and safer combinations.
  

Bayartis also writes publicly about deprescribing—the supervised reduction of unnecessary medications—signaling a clinically thoughtful stance, not just a gadget play. Their team discusses models to detect harmful combinations and support decision-making—the kind of AI that can augment clinicians and caregivers.

🧩 What Makes Bayartis Stand Out

• AgeTech-first mission: Designed for seniors to stay healthy at home—safety, simplicity, and independence lead the roadmap.
  
• Human-centered device + software: The cabinet makes the invisible visible; the app reduces cognitive load with notifications and context.
  
• Content and literacy lens: Their glossary and publishing cadence signal a brand investing in patient education, not just tech.
  
• Market traction signals: Listed as an exhibitor at MEDICA 2025 (Hall 12, D19)—a strong venue for MedTech validation and partnerships.
  

👥 The Team Behind the Mission

• Fatma Özdemir-Zäch, Founder & CEO — 25+ years in pharma and life sciences (incl. Novartis), with Medical Informatics and Life Sciences MBA credentials.
  Team page → https://www.bayartis.com/team
  
• Sadik Keshwani, Co-founder/CTO — product/technology leader passionate about solving polypharmacy at scale.
  LinkedIn → https://www.linkedin.com/in/keshwani
  

For company updates: Bayartis on LinkedIn and the Bayartis Thinking publication.

🤝 YOUR R&D × Bayartis: Synergy Opportunities

At YOUR R&D, we specialise in full-cycle HealthTech software and AI, DevOps, and SDLC excellence—with a track record across clinical and patient-facing products. Here are collaboration threads where we can accelerate Bayartis’ roadmap:

Device–Cloud Architecture & Interoperability

• Edge → cloud pipeline for the smart cabinet (secure firmware updates, telemetry, anomaly detection).
  
• FHIR-based interoperability to surface adherence and adverse-event insights to providers/EHRs.
  
• High-availability .NET + JS stacks to scale consumer apps while meeting healthcare security baselines.
  

AI/ML for Safety, Detection & Personalisation

• Interaction risk models and signal detection for side-effects using curated datasets and model governance aligned with FDA/IMDRF expectations for AI-enabled medical devices.
  
• Personalised nudging to improve adherence (context-aware reminders, caregiver loops) with transparent, auditable ML.
  

Regulatory Readiness & QMS Support

• Support for Software as a Medical Device (SaMD) pathways; documentation, risk management, and post-market monitoring data flows.
  
• Privacy by design and data protection aligned to EU expectations (building on Bayartis’ existing privacy stance).
  

Go-to-Market & Clinical Narrative

• Content frameworks that bridge consumers, caregivers, and clinicians (deprescribing education, med-safety moments).
  
• Pilot design with payers/providers to quantify reductions in ADEs and readmissions—clear ROI storytelling.
  

We already track Bayartis in our Web Summit 2024 pipeline (Startup CSV)—happy to coordinate intros and a short technical discovery to explore the above.

🔗 Useful Links

• Bayartis website: (mission, product, blog).
  
• YOUR R&D homepage: (services in AI & full-stack HealthTech).
  
• YOUR R&D blog (related reads & case thinking)